GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: Dalutrafusp alfa
Drug: mFOLFOX6 Regimen

First Posted Date: 2019-05-17

Last Posted Date: 2023-11-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 22

Registration Number: NCT03954704

Locations: 🇺🇸
Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale, Arizona, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 1 locations

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Phase 1

Terminated

Conditions: Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer

Interventions: Drug: KITE-439
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2

First Posted Date: 2019-04-11

Last Posted Date: 2023-12-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 8

Registration Number: NCT03912831

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin
Drug: Sacituzumab Govitecan-hziy
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine

First Posted Date: 2019-04-03

Last Posted Date: 2024-10-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 543

Registration Number: NCT03901339

Locations: 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Maryland Oncology Hematology, P.A., Rockville, Maryland, United States

and more 110 locations

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Phase 3

Terminated

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Cilofexor
Drug: Placebo

First Posted Date: 2019-03-26

Last Posted Date: 2023-11-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 419

Registration Number: NCT03890120

Locations: 🇺🇸
Texas Clinical Research Institute, Arlington, Texas, United States
🇺🇸
Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 198 locations

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

Phase 3

Completed

Conditions: Chronic Hepatitis Delta

Interventions: Drug: Bulevirtide

First Posted Date: 2019-02-25

Last Posted Date: 2024-12-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 150

Registration Number: NCT03852719

Locations: 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik 1, Frankfurt am Main, Germany
🇮🇹
Università di Modena e Reggio Emilia- Ospedale Civile S., Modena, Italy
🇺🇸
Cornell University Well Madical College, New York, New York, United States

and more 16 locations

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Phase 2

Completed

Conditions: Chronic Hepatitis Delta

Interventions: Drug: Bulevirtide
Drug: Peginterferon Alfa-2a (PEG-IFN alfa)

First Posted Date: 2019-02-25

Last Posted Date: 2024-10-08

Lead Sponsor: Gilead Sciences

Target Recruit Count: 175

Registration Number: NCT03852433

Locations: 🇷🇺
LLC Medical Company "Hepatolog", Samara, Russian Federation
🇷🇺
Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service on Consumers Rights Protection and Human Well-Being Surveillance, Moscow, Russian Federation
🇷🇺
State Budgetary Educational Institution of Higher Professional Education "South Ural State Medical University" of the Ministry of Healthcare of the Russian Federation, Chelyabinsk, Russian Federation

and more 17 locations

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Phase 2

Terminated

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL/VOX

First Posted Date: 2019-01-29

Last Posted Date: 2020-10-23

Lead Sponsor: Gilead Sciences

Target Recruit Count: 21

Registration Number: NCT03820258

Locations: 🇮🇹
SOS-intraSOC Epatologia, Firenze, Italy
🇮🇹
US Infettivologia Pediatrica-Polo Universitario, Milano, Italy
🇮🇹
Servizio di Epatologia e Nutrizione Pediatrica, Milan, Italy

and more 7 locations

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Phase 1

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Lenacapavir
Drug: Placebo
Drug: TAF
Drug: B/F/TAF

First Posted Date: 2018-11-14

Last Posted Date: 2021-04-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 53

Registration Number: NCT03739866

Locations: 🇺🇸
Orlando Immunology Center PA, Orlando, Florida, United States
🇺🇸
Mills Clinical Research, Los Angeles, California, United States
🇺🇸
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

and more 9 locations

Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

Terminated

Conditions: B-cell Malignancies

Interventions: Biological: Influenza Vaccine

First Posted Date: 2018-10-10

Last Posted Date: 2020-02-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 2

Registration Number: NCT03701438

Locations: 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇨🇿
Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague 10, Czechia

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: B/F/TAF
Drug: NRTIs
Drug: Third Agent

First Posted Date: 2018-08-15

Last Posted Date: 2021-09-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 496

Registration Number: NCT03631732

Locations: 🇺🇸
Whitman-Walker Health, Washington, District of Columbia, United States
🇺🇸
University Medical Center- New Orleans (UMCNO), New Orleans, Louisiana, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

and more 78 locations

Home Terms & Conditions Privacy Policy